Barry Jones

5.1k total citations · 1 hit paper
63 papers, 3.6k citations indexed

About

Barry Jones is a scholar working on Pharmacology, Molecular Biology and Spectroscopy. According to data from OpenAlex, Barry Jones has authored 63 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pharmacology, 19 papers in Molecular Biology and 18 papers in Spectroscopy. Recurrent topics in Barry Jones's work include Pharmacogenetics and Drug Metabolism (46 papers), Analytical Chemistry and Chromatography (16 papers) and Drug Transport and Resistance Mechanisms (16 papers). Barry Jones is often cited by papers focused on Pharmacogenetics and Drug Metabolism (46 papers), Analytical Chemistry and Chromatography (16 papers) and Drug Transport and Resistance Mechanisms (16 papers). Barry Jones collaborates with scholars based in United Kingdom, United States and Sweden. Barry Jones's co-authors include Dennis A. Smith, Ruth Hyland, Mark J. Ackland, S. Ball, Susan Hurst, Theunis C. Goosen, J. Andrew Williams, Jeffrey R. Koup, Vincent Peterkin and Marcel J. de Groot and has published in prestigious journals such as Biochemistry, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Barry Jones

63 papers receiving 3.4k citations

Hit Papers

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SU... 2004 2026 2011 2018 2004 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
    2004 687 citations Ruth Hyland, Barry Jones et al. Drug Metabolism and Disposition profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry Jones United Kingdom 29 2.1k 1.1k 1.1k 914 583 63 3.6k
Robert J. Riley United Kingdom 35 2.3k 1.1× 1.1k 1.0× 1.6k 1.5× 690 0.8× 426 0.7× 75 4.1k
Larry C. Wienkers United States 33 2.6k 1.2× 947 0.9× 1.2k 1.2× 571 0.6× 307 0.5× 79 3.9k
Ken Korzekwa United States 27 2.2k 1.0× 937 0.9× 1.6k 1.4× 461 0.5× 377 0.6× 67 3.4k
Barbara J. Ring United States 36 2.7k 1.2× 1.0k 0.9× 1.5k 1.4× 625 0.7× 452 0.8× 59 4.7k
Kenneth R. Korzekwa United States 34 2.7k 1.3× 1.1k 1.0× 1.2k 1.1× 658 0.7× 458 0.8× 63 3.9k
Slobodan Rendić Croatia 20 2.1k 1.0× 870 0.8× 972 0.9× 419 0.5× 309 0.5× 45 3.2k
Hannah M. Jones United States 36 1.4k 0.7× 1.1k 1.0× 1.3k 1.2× 493 0.5× 384 0.7× 105 3.8k
Richard Weaver United Kingdom 36 1.7k 0.8× 1.2k 1.1× 1.2k 1.1× 386 0.4× 232 0.4× 86 3.9k
José Cosme France 16 2.0k 0.9× 1.0k 0.9× 841 0.8× 754 0.8× 439 0.8× 24 2.8k
Neil Parrott Switzerland 37 1.5k 0.7× 1.0k 1.0× 1.3k 1.2× 516 0.6× 578 1.0× 125 4.5k

Countries citing papers authored by Barry Jones

Since Specialization
Citations

This map shows the geographic impact of Barry Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Jones more than expected).

Fields of papers citing papers by Barry Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Jones. The network helps show where Barry Jones may publish in the future.

Co-authorship network of co-authors of Barry Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Jones. A scholar is included among the top collaborators of Barry Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Jones. Barry Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colclough, Nicola, Scott E. Martin, Martin Wild, et al.. (2025). Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase. Drug Metabolism and Disposition. 53(8). 100107–100107. 1 indexed citations
2.
Martin, Scott, et al.. (2020). Drug metabolite identification using ultrahigh‐performance liquid chromatography–ultraviolet spectroscopy and parallelized scans on a tribrid Orbitrap mass spectrometer. Rapid Communications in Mass Spectrometry. 34(10). e8735–e8735. 12 indexed citations
3.
4.
Pointon, Amy, et al.. (2018). Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. Drug Metabolism and Disposition. 46(8). 1053–1065. 53 indexed citations
5.
Jones, Barry, Abhishek Srivastava, Nicola Colclough, et al.. (2017). An Investigation into the Prediction of In Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates. Drug Metabolism and Disposition. 45(10). 1060–1067. 23 indexed citations
6.
Jones, Barry, et al.. (2017). CYP-Mediated Sulfoximine Deimination of AZD6738. Drug Metabolism and Disposition. 45(11). 1133–1138. 9 indexed citations
7.
Hariparsad, Niresh, Diane Ramsden, Jairam Palamanda, et al.. (2017). Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control. Drug Metabolism and Disposition. 45(10). 1049–1059. 33 indexed citations
8.
Stresser, David M., et al.. (2013). Exploring concepts ofin vitrotime-dependent CYP inhibition assays. Expert Opinion on Drug Metabolism & Toxicology. 10(2). 157–174. 35 indexed citations
9.
10.
Johnson, Trevor N., Thomas Kerbusch, Barry Jones, et al.. (2009). Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: usingin vitrodata as an aid to assess study power. Pharmaceutical Statistics. 8(3). 186–202. 11 indexed citations
11.
Jones, Barry, Donald S. Middleton, & Kuresh Youdim. (2009). 6 Cytochrome P450 Metabolism and Inhibition: Analysis for Drug Discovery. Progress in medicinal chemistry. 47. 239–263. 7 indexed citations
12.
Hyland, Ruth, et al.. (2009). In vitroandin vivoglucuronidation of midazolam in humans. British Journal of Clinical Pharmacology. 67(4). 445–454. 66 indexed citations
13.
Hyland, Ruth, Maurice Dickins, Claire Collins, Hannah M. Jones, & Barry Jones. (2008). Maraviroc:in vitroassessment of drug–drug interaction potential. British Journal of Clinical Pharmacology. 66(4). 498–507. 72 indexed citations
14.
Youdim, Kuresh, et al.. (2008). An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC–MS/MS end-point. Journal of Pharmaceutical and Biomedical Analysis. 48(1). 92–99. 49 indexed citations
15.
Mirghani, Rajaa A., Jane Sayi, Eleni Aklillu, et al.. (2006). CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenetics and Genomics. 16(9). 637–645. 63 indexed citations
16.
Hyland, Ruth, Barry Jones, & H. Van De Waterbeemd. (2005). Utility of human/human-derived reagents in drug discovery and development: An industrial perspective. Environmental Toxicology and Pharmacology. 21(2). 179–183. 3 indexed citations
17.
Middleton, Donald S., et al.. (2005). Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption. Bioorganic & Medicinal Chemistry Letters. 15(17). 3957–3961. 6 indexed citations
18.
Williams, John A., Susan Hurst, Jonathan Bauman, et al.. (2003). Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence?. Current Drug Metabolism. 4(6). 527–534. 39 indexed citations
19.
Hyland, Ruth, et al.. (2001). Identification of the cytochrome P450 enzymes involved in the N‐demethylation of sildenafil. British Journal of Clinical Pharmacology. 51(3). 239–248. 137 indexed citations
20.
Jones, Barry, et al.. (1997). Synthetic strategies to lower affinity for CYP2D6. European Journal of Drug Metabolism and Pharmacokinetics. 22(4). 291–294. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert J. Riley Breakdown of academic impact, for papers by Larry C. Wienkers Breakdown of academic impact, for papers by Ken Korzekwa Breakdown of academic impact, for papers by Barbara J. Ring Breakdown of academic impact, for papers by Kenneth R. Korzekwa Breakdown of academic impact, for papers by Slobodan Rendić Breakdown of academic impact, for papers by Hannah M. Jones Breakdown of academic impact, for papers by Richard Weaver Breakdown of academic impact, for papers by José Cosme Breakdown of academic impact, for papers by Neil Parrott
Rankless by CCL
2026